Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 268 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Midazolam Alone Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human Study of VX-433

NCT07584434
View directory record Official record
Conditions
Narcolepsy Type 1 (NT1)
Interventions
VX-433, Placebo, Midazolam, Bupropion
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

NCT02857270
View directory record Official record
Conditions
Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
Interventions
LY3214996, Midazolam, Abemaciclib, Nab-paclitaxel, Gemcitabine, Encorafenib, Cetuximab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Sarasota, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 19, 2026, 12:32 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395

NCT07820891
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
BGB-43395, Midazolam, Celecoxib, Dabigatran etexilate, Rosuvastatin
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional

Spreading Depolarization and Ketamine Suppression

NCT02501941
View directory record Official record
Conditions
Cortical Spreading Depolarization, Cortical Spreading Depression, Subarachoid Hemorrhage, Traumatic Brain Injury
Interventions
ketamine
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men

NCT04713254
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06466, Midazolam, Metoprolol, Bupropion
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 19, 2026, 12:32 PM EDT
Recruiting Phase 3 Interventional

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

NCT05208047
View directory record Official record
Conditions
Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
Interventions
CGT9486, Sunitinib, Midazolam
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Terminated Not applicable Interventional Results available

Propofol vs Propofol + Benzo/Opiates in High Risk Group

NCT01315158
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Obesity
Interventions
Propofol Alone, Propofol+Benzo/Opioids
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion

NCT02085967
View directory record Official record
Conditions
Healthy Subjects
Interventions
rifampin 600 mg, itraconazole 200 mg, midazolam 2 mg with bupropion 75 mg, E2006
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects

NCT02147808
View directory record Official record
Conditions
Drug Interactions
Interventions
Telotristat etiprate, Midazolam
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector

NCT00534378
View directory record Official record
Conditions
Seizures
Interventions
Midazolam
Drug
Lead sponsor
U.S. Army Office of the Surgeon General
Federal
Eligibility
18 Years to 54 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2007 · Synced Oct 19, 2026, 12:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole
Drug
Lead sponsor
Nuvalent Inc.
Industry
Eligibility
12 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
21
States / cities
Orange, California • Sacramento, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

NCT03358706
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Cypress, California • Miami Springs, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Not applicable Interventional

Acupuncture for the Prevention of Emergence Delirium in Children Undergoing Myringotomy Tube Placement

NCT02383004
View directory record Official record
Conditions
Delirium, Psychomotor Agitation
Interventions
Acupuncture
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Year to 6 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

NCT04147715
View directory record Official record
Conditions
Healthy Volunteer
Interventions
S-648414, Placebo, Midazolam, Dolutegravir
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 19, 2026, 12:32 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

NCT05671653
View directory record Official record
Conditions
Obesity
Interventions
PF-07081532, Semaglutide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 19, 2026, 12:32 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD

NCT02206776
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Intranasal Ketamine, Intranasal Midazolam
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 19, 2026, 12:32 PM EDT
Suspended Phase 4 Interventional

IM Ketamine vs Midazolam for Suicidal ER Patients

NCT04640636
View directory record Official record
Conditions
Depression, Unipolar, Depression, Bipolar, Suicidal Ideation
Interventions
Ketamine hydrochloride injection, Midazolam injection
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

NCT01585623
View directory record Official record
Conditions
Solid Tumor
Interventions
SAR302503, omeprazol, metoprolol, midazolam
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Augusta, Georgia • Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014)

NCT07838987
View directory record Official record
Conditions
Healthy
Interventions
TERN-701, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine
Drug
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 4 Interventional

Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy

NCT02193568
View directory record Official record
Conditions
Adult Brain Tumor
Interventions
Arm I (light sedation), Arm II (intubated general anesthesia), Arm II (intubated general anesthesia), Arm I (light sedation)
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CP-690,550 and Midazolam Drug-Drug Interaction Study

NCT00902460
View directory record Official record
Conditions
Healthy Volunteer
Interventions
midazolam; CP-690,550 + midazolam, CP-690,550 + midazolam; midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2009 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects

NCT01402076
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tasimelteon, Rosiglitazone, Midazolam
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 17, 2014 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions

NCT03234699
View directory record Official record
Conditions
Healthy
Interventions
Cenobamate, midazolam, Warfarin Pill, Omeprazole Pill, Bupropion Pill
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Memory Modulation by Pain During Anesthesia

NCT02515890
View directory record Official record
Conditions
Amnesia, Pain, Anesthesia
Interventions
Dexmedetomidine, Midazolam, Peripheral nerve stimulation, Ketamine
Drug · Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 39 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 19, 2026, 12:32 PM EDT